BRINGING CLINICIANS TOGETHER TO DISCUSS CURRENT DRUG THERAPY

June 2018 • Vol. 15, No. 6
The following succinct analysis appeared in Pharmacist’s Letter. Based on vol. 34. No. 6

DIABETES
Experts will debate how often patients with type 2 diabetes should check their blood glucose.

We know that type 2 patients on multiple daily insulin doses should routinely monitor glucose.

But evidence is mixed about whether routine checks improve A1C or reduce hypoglycemia in other patients with type 2 diabetes.

Plus testing can be costly...and results often go unused.

On the other hand, advocates say studies have flaws...and monitoring can help patients see the impact of meds and lifestyle changes.

Use a “common sense” approach...since monitoring is more art than science. Consider glycemic control, risk of hypoglycemia, etc.

As a rule of thumb, advise routine monitoring only if the results will be used to make treatment changes.

For example, in type 2 patients with poor glycemic control, advise checking glucose 3 to 4 times a week to see if med changes are making headway...or checking daily when titrating basal insulin.

But less frequent checks are often okay for patients at or close to A1C goal...along with checking for hypoglycemia symptoms or acute illness.

Generally suggest fasting checks. But if fasting results are normal and A1C is high, occasional postprandial monitoring can show if sugars after meals are driving up A1C...and can educate about the impact of diet.

Train patients how to use their meter...troubleshoot problems...and track and share results. Also teach target ranges... 80 to 130 mg/dL before meals or less than 180 mg/dL after meals.

Get more tips in our chart, Self-Monitoring of Blood Glucose in Type 2 Diabetes, and see our chart, Continuous Glucose Monitoring FAQs, for CGM advice. Also share our handout, Understanding Blood Sugar Numbers.

(For more on this topic, see Clinical Resource #340604 at PharmacistsLetter.com.)


See LEADER NOTES for answers to discussion questions.
DISCUSSION QUESTIONS

OVERVIEW OF CURRENT THERAPY

1. What is known about self-monitoring of blood glucose (SMBG) and how it affects patient outcomes?

ANALYSIS OF NEW STUDY

2. What type of study was this? How were the patients selected for inclusion?

3. How were the study groups defined?

4. How were the outcomes evaluated?

5. What were the outcomes of this trial?

See LEADER NOTES for answers to discussion questions.
6. What were the strengths and weaknesses of this study?

7. Were the results expressed in terms we care about and can use?

HOW SHOULD THE NEW FINDINGS CHANGE CURRENT THERAPY?

8. Do the results change your practice? How?

APPLY THE NEW FINDINGS TO THE FOLLOWING CASE

H.S. is a 61-year-old Caucasian female with a past medical history of obesity and hypertension that’s well controlled on amlodipine 10 mg daily. She’s in clinic today to follow-up on lab work from her last visit, which was notable for a glucose of 247 mg/dL. Although H.S. doesn’t have symptoms of diabetes, she is concerned about her elevated glucose result, since her husband has diabetes and is on insulin therapy.

You obtain a point-of-care A1C on H.S. and it returns at 10.1%. You explain to H.S. that she does have diabetes and discuss treatment options. She does not want to be on insulin if it can be avoided, as she has seen her husband have to check his blood sugar many times per day, deal with multiple injections, and also combat episodes of hypoglycemia.
9. **What treatment should you consider first-line to treat H.S.’s diabetes? What other medications should be considered for patients with type 2 diabetes?**

You discuss diet and exercise modifications and also start H.S. on metformin 500mg daily, with the plan to titrate up to 1,000 mg twice daily over the next four weeks. You also discuss starting H.S. on atorvastatin 80mg daily, since her estimated ten-year CV risk is above 7.5%. However, you hold off on recommending low-dose aspirin for primary CV prevention, since the net benefit for H.S. is likely small. You continue H.S.’s amlodipine since her hypertension is well-controlled.

H.S. agrees to start metformin and atorvastatin. She also asks how often she should check her blood sugar, since she is used to seeing her husband check frequently.

10. **How often should patients with type 2 diabetes check their glucose? How should you advise H.S.?**

You advise H.S. to check her glucose three to four times a week in the morning before she has eaten. You ask H.S. to record her results, and to bring them with her to clinic visits.

H.S. returns in 1 month for follow-up and brings a log of her fasting sugars. She has successfully titrated metformin to 1000mg twice daily, has changed her dietary habits, and is walking 20 to 30 minutes daily. She has lost 8 pounds since her last visit and is pleased with her progress. You note that her blood sugar log shows a decrease in her fasting sugars over the last month, with results generally 160 to 180 mg/dL.

11. **Should you consider medication changes for H.S. at this time?**

See LEADER NOTES for answers to discussion questions.
REFERENCES


Additional Pharmacist’s Letter Resources available at PharmacistsLetter.com


See LEADER NOTES for answers to discussion questions.
PLJournal Club Contributing Editors:

Lori Dickerson, PharmD, FCCP, Editor; Jennifer Nieman, PharmD, BCPS, Associate Editor; Lisa D. Mims, MD, Department of Family Medicine, Medical Univ of South Carolina, Charleston, SC; Maribeth Porter, MD, Department of Community Health and Family Medicine, Univ of Florida, Gainesville, FL.

Editors and Authors: Jeff Elin, PharmD, Editor-in-Chief; Sheli Boehringer, PharmD, Senior Editor, VP Content; Karen Davidson, PharmD, Senior Editor Emeritus; Tammie Blair, MPH, PharmD, FASHP, FCCP, BCPS, Sandye Chabot, PharmD; Lori Dickerson, PharmD, FCCP; Rachel Maynard, PharmD; Kimberly Palaciozo, PharmD, Editors; Stacy Hester, RPh, BCPS; Crystal Maric, BSc; Pharm, MBA, ACRP, Jennifer Nieman, PharmD, BCPS, Associate Editors; Bethany Bryant, PharmD, BCPS; Vickie Danner, PharmD; Leslie Gingo, PharmD, BCPS; Flora Harp, PharmD; Tanner Higginbotham, PharmD; Jeff Langford, PharmD, BCPS; Cardiology; Tonye Ripley, PharmD, FCCP, BCPS; Cardiology, ASH-Chic; Beata Rowan, PharmD, BCPS; James Van, BSc; Pharm; Don Weinberger, PharmD; Marlea Wellein, PharmD, BCPS, Associate Editors; Karen Wilson, BA, Manuscript Editor; Mindy Paglina wan, BA, Assistant Manuscript Editor; Jenni Mangrum, BS, CPhT, Assistant Education and Accreditation Editor, Mark Graber, MD, MSHCE, FACEP, Associate Clinical Editor. Consultants: Jeff Allen, PharmD, PBS; Melanie Cupp, PharmD, BCPS; John Greis, BSc, Pharm, JD, LLM; Katie Lacaria, BSc, Pharm, ACRP; Heidi Liston, BSc Pharm, PharmD; Lu-Ann Murdoch, BSc Pharm; Annette Murray, BSc Pharm; Jennifer Pennington, RN, BSN. Editorial Advisors: Christopher Anslinger, PA-C; Thomas Baringer, MD, FAHA, FNA, Christopher Barry, PA-C, MMS; William Bednar, MD; Larissa Bosaer, PharmD, BCPS; Robert Brown, MD, FAAP; Stephen Brunt, MD; Holley Bush, PharmD; Peter Carek, MD, MS; Gary Choy, PharmD; Matthew Cline, MD; John Connolly, MD, FACP, FCCP; Sandra Counts, PharmD, BCPS; Fikret Fikrat, PhD, Rex Force, PharmD, FCCP; Lawrence Frank, MD, FACP, Peter Garbeff, MD, Mark Garofoli, PharmD, MBA, CGP; Denise Gonticz, FNP-C; Charles Green, RPh; John Hambright, PharmD; Roland Hart, MD; Kyle Herbold, MD; Patricia Hatton, MD; Sydney Hendry, MD; Raissa Hill, DO; Jerry Jones, MD; Sheila Kapre, MD, FACP, FCCP; Adam Kaye, PharmD, FASCP, FCPhA; William Kehoe, PharmD, MA, FACC, BCPS; Joshua Lenchus, DO, RPh, FACP, FHM; Stanley Leong, PharmD;Kevin Maeda, PharmD; Christine Manch, RPh; Eric Matheson, MD, MS; Christina McGrail, MD, CPMT, EMT; Ken Niegel, RPh; Mike Pastick, RPh; Ernest Pierer, PharmD; Daren Primack, MD, FACC; Barbara Rankin, MD; Jenna Reel, PharmD, BCPS, CPP, CDE; George Rishwain, MD; Sandy Robertson, PharmD; Edward Rogan, PharmD, BCACP; Gerald Ruble, MSc, PharmD; Ruth Ruffe, PharmD; AnnieMarie Santos, MD; David Schneider, MD, Allen Shaughnessy, PharmD, MMED; Jonathan Skotak, PharmD, BACP; Joshua Tesser, DO; Bruce Ueh, PharmD; John David Williamson, MD, FAAP; Raymond Wong, MD; William Yee, PharmD, FASHP, FCSHP; Kent Yeg, RPh.

Advisory Board: Evan Ballard, MD, Jonesville Family Medical Ctr; Melvin Baron, PharmD, MPA, Univ of Southern Calif; Jan Basle, MD, FACP, Medical Univ of South Carolina; Robert Bickerton, MD, FACP; Reid B. Blackwelder, MD, FAAP; East Tennessee State Univ; Kevin Brown, MD, FACOG, Texas AM; Andrea Darby-Stewart, MD, HonorHealth; Anthony A. Donato, Jr., MD, MHPE; Reading Health System; Jan Drutz, MD, Baylor College of Med; Margaret A. Fitzgerald, DNP, NP-BC, NP-C, FAANP, CSP, FAAN, DCC, Fitzgerald Health Ed Associates, Barry Gidal, PharmD, RPh, Univ of Sisc; Robert Gottfried, DO, FACP; Martin Grajower, MD, BCPS, FACEP; Albert Einstein College of Med; B Joseph Guglielmo, PharmD, UC San Francisco; Stuart Haines, PharmD, BCPS; BCACP, BC-ADM, FCCP, FASHP, FAPA, Univ of Miss; Jeffrey Haman, Jr, MD, Col, USAF, MC, FS, B Mark Hess, MD, FACP; John Holman, MD, MPH, FAAP; Eric Jackson, PharmD, FCPhC, BCP, Univ of Conn; Peter Jacobsen, PhD, DDS, Univ of the Pacific; Paul Jensen, MD, PharmD, FAAP; Alan David Kaye, MD, PhD, DABA, DABPM, DABPP, Louisiana State Univ; Steve Kayser, PharmD, UC San Francisco; Brian Kessler, DO, FAACFP, Lincoln-Memorial Univ; Edgar Lema, MD, FACP, FASN, FAHA, Univ of Illinois at Chicago; Evan L Lipis, MD; Mark McConnell, MD, Oscar G. Johnson VA Medical Ctr; Stephen L. McKean, BSc, Pharm, MD, DO, FAAP, Sam Houston State Univ; Steven E. Nissen, MD, MACh, Cleveland Clinic; Brenda O’Hara, RPh, BCACP, Blue Cross Blue Shield of NC; Douglas S. Pauw, MD, MACP, Univ of Washington; Dan Pen, BSc, Pharm, MD, FRCPC, McMaster Univ; Charles Ponte, BS, PharmD, FAFAE, FAPhA, BCACP, FNAP, West Virginia Schools of Pharmacy & Medicine; Joseph E. Scherger, MD, MPH, Eisenhower Medical Ctr; Arthur Shinn, PharmD, FASCP, Managed Pharmacy Consultants; Kelly Anne Spratt, DO, FACC, University of Pennsylvania; Dan Steiber, RPh, GenesisPharma Consultants; Tom Vicker, PharmD, OPTION Care; C. Wayne Weart, PharmD, FAPhA, FASHP, BCPS, Medical Univ of South Carolina; Craig D. Williams, PharmD, FNA, BCPS, Oregon Health & Science Univ.

DISCLOSURE: The editors of this activity and its publisher, Therapeutic Research Center, have no relevant financial interests related to the products or services covered by this activity. Therapeutic Research Center/PharmacistsLetter does not receive any commercial support and does not accept any advertising. It is completely independent and is supported entirely by subscriptions. PharmacistsLetter focuses on delivering completely objective, unbiased drug information and advice for the benefit of subscribers.

Unbiased Evidence and Recommendations for the Pharmacist on New Developments in Drug Therapy
3120 West March Lane, Stockton, CA  95219
TEL (209) 472-2240 ~ FAX (209) 472-2249
PharmacistsLetter.com

The contents are copyrighted. © 2018 Therapeutic Research Center. All Rights Reserved.

See LEADER NOTES for answers to discussion questions.